These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
808 related articles for article (PubMed ID: 17494760)
1. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760 [TBL] [Abstract][Full Text] [Related]
2. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201 [TBL] [Abstract][Full Text] [Related]
3. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991 [TBL] [Abstract][Full Text] [Related]
4. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Mahajan NP; Whang YE; Mohler JL; Earp HS Cancer Res; 2005 Nov; 65(22):10514-23. PubMed ID: 16288044 [TBL] [Abstract][Full Text] [Related]
5. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705 [TBL] [Abstract][Full Text] [Related]
6. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Mahajan K; Challa S; Coppola D; Lawrence H; Luo Y; Gevariya H; Zhu W; Chen YA; Lawrence NJ; Mahajan NP Prostate; 2010 Sep; 70(12):1274-85. PubMed ID: 20623637 [TBL] [Abstract][Full Text] [Related]
7. Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding. Karaca M; Liu Y; Zhang Z; De Silva D; Parker JS; Earp HS; Whang YE PLoS One; 2015; 10(5):e0126270. PubMed ID: 25950519 [TBL] [Abstract][Full Text] [Related]
8. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566 [TBL] [Abstract][Full Text] [Related]
10. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Chen T; Wang LH; Farrar WL Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674 [TBL] [Abstract][Full Text] [Related]
11. Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen. De Silva D; Zhang Z; Liu Y; Parker JS; Xu C; Cai L; Wang GG; Earp HS; Whang YE Sci Rep; 2019 Dec; 9(1):18637. PubMed ID: 31819114 [TBL] [Abstract][Full Text] [Related]
12. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455 [TBL] [Abstract][Full Text] [Related]
15. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860 [TBL] [Abstract][Full Text] [Related]
16. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells. Hsu FN; Yang MS; Lin E; Tseng CF; Lin H Am J Physiol Endocrinol Metab; 2011 May; 300(5):E902-8. PubMed ID: 21364123 [TBL] [Abstract][Full Text] [Related]
18. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Meng TC; Lee MS; Lin MF Oncogene; 2000 May; 19(22):2664-77. PubMed ID: 10851066 [TBL] [Abstract][Full Text] [Related]
19. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. Mahajan K; Lawrence HR; Lawrence NJ; Mahajan NP J Biol Chem; 2014 Oct; 289(41):28179-91. PubMed ID: 25148682 [TBL] [Abstract][Full Text] [Related]
20. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Gnanapragasam VJ; Robson CN; Neal DE; Leung HY Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]